Scarica l'app Stockscreener
4.64
34.10%
1.18
Dopo l'orario di chiusura:
4.75
0.11
+2.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Precedente Chiudi:
$3.46
Aprire:
$5.78
Volume 24 ore:
75.11M
Relative Volume:
17.98
Capitalizzazione di mercato:
$597.02M
Reddito:
-
Utile/perdita netta:
$-110.78M
Rapporto P/E:
-5.3333
EPS:
-0.87
Flusso di cassa netto:
$-75.59M
1 W Prestazione:
+13.17%
1M Prestazione:
+5.22%
6M Prestazione:
-11.45%
1 anno Prestazione:
+69.34%
Intervallo 1D:
$4.45
$6.77
Intervallo di 1 settimana:
$3.37
$6.77
Portata 52W:
$2.48
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Nome
Humacyte Inc
Settore
Industria
Telefono
919-313-9633
Indirizzo
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Confronta HUMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
4.64 | 597.02M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-14 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Downgrade | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Iniziato | Cowen | Outperform |
| 2021-09-24 | Iniziato | Oppenheimer | Outperform |
| 2021-09-22 | Iniziato | BTIG Research | Buy |
| 2021-09-16 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Humacyte Inc Borsa (HUMA) Ultime notizie
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $596,000 in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, - GlobeNewswire
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
Humacyte, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
Humacyte Receives FDA Approval for SYMVESS Launch - TipRanks
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine - Endpoints News
FDA approval propels North Carolina company's breakthrough treatment for trauma patients - The Business Journals
Humacyte’s tissue-engineered graft for vascular trauma approved by FDA - BioWorld Online
Shareholders That Lost Money on Humacyte, Inc. (HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - AccessWire
US FDA approves Humacyte’s Symvess for vascular trauma - Vascular News
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte Stock Hits Over 1-Month Highs On FDA Nod For Bioengineered Tissue In Treating Vascular Trauma, Retail - Asianet Newsable
Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Humacyte (NASDAQ:HUMA) Shares Gap UpHere's Why - MarketBeat
Spotlight on Humacyte: Analyzing the Surge in Options Activity - Benzinga
Huma Stock Surges Following FDA Approval of Groundbreaking Bioengineered Vascular Conduit - The Africa Logistics
BTIG reiterates Buy on Humacyte stock as FDA approval of SYMVESS boosts commercialization prospects - Investing.com South Africa
Humacyte's (HUMA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Humacyte's bioengineered human tissue gains FDA approval - FirstWord Pharma
Humacyte shares target raised, buy rating held on FDA approval - Investing.com
Humacyte surges on FDA approval for Symvess vascular repair product - MSN
Humacyte stock surges on Symvess FDA approval (HUMA:NASDAQ) - Seeking Alpha
Humacyte stock surges over 50% on FDA approval - Investing.com
Humacyte Shares Surge 38% on FDA Approval of Symvess - Marketscreener.com
Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Jo - GuruFocus.com
Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone' - Benzinga
FDA Approves Humacyte's Groundbreaking Bioengineered Blood Vessel Treatment SYMVESS in Historic First - StockTitan
Humacyte's SYMVESS gets FDA nod for vascular trauma - Investing.com
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma - The Manila Times
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
Humacyte’s (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles – Hagens Berman - GlobeNewswire
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – HUMA - EIN News
Humacyte, Inc. Class Action Lawsuit Alert: Johnson Fistel - GlobeNewswire
Humacyte, Inc. (NASDAQ:HUMA) Holdings Boosted by Fmr LLC - Defense World
Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your RightsHUMA - PR Newswire
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
Class Action Filed Against Humacyte, Inc. (HUMA)January 17, 2025 Deadline to JoinContact Levi & Korsinsky - AccessWire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. - EIN News
Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60m - Yahoo Finance
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - PR Newswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. Investors of - EIN News
Humacyte's SWOT analysis: HAV tech stock shows promise amid safety concerns - Investing.com
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Humacyte, - GlobeNewswire
Humacyte (NASDAQ:HUMA) Stock Price Down 6.7%Time to Sell? - MarketBeat
Investors who lost money on Humacyte, Inc. (HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - AccessWire
Humacyte Inc Azioni (HUMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):